What is the proper dosing and administration of Glycoair (glycopyrrolate/formoterol fumarate) for a patient with severe Chronic Obstructive Pulmonary Disease (COPD) and a history of exacerbations?

Glycopyrrolate/Formoterol Fumarate (GFF MDI) Dosing and Administration for Severe COPD

The recommended dose is 18 mcg glycopyrrolate/9.6 mcg formoterol fumarate (two inhalations) administered twice daily via metered dose inhaler, with no dose adjustments needed based on age, gender, or disease severity. 1

Standard Dosing Regimen

• Administer GFF MDI 18/9.6 mcg (two inhalations) twice daily - this is the only approved dose for COPD maintenance therapy 1, 2, 3
• Do not exceed the recommended dose of 20 mcg formoterol twice daily, as increasing beyond this provides no additional benefit and increases risk of cardiovascular adverse effects 1
• GFF MDI should be taken at approximately the same times each morning and evening, roughly 12 hours apart 1

Critical Administration Instructions

• This is maintenance therapy only - never use for acute symptom relief or rescue therapy 1
• Prescribe a separate short-acting beta-2 agonist (SABA) for acute bronchospasm and instruct patients to discontinue regular scheduled SABA use (e.g., four times daily) once GFF MDI is initiated 1
• Do not use in conjunction with other long-acting beta-2 agonists or long-acting muscarinic antagonists to avoid overdose 1
• Never initiate GFF MDI during acute exacerbations or acutely deteriorating COPD - this is inappropriate and potentially life-threatening 1

Patient Selection for Severe COPD with Exacerbation History

For patients with severe COPD and exacerbation history, GFF MDI significantly reduces exacerbation risk by 28% compared to placebo, with greater benefits in symptomatic patients (CAT score ≥15) and those with prior exacerbations 3. The pooled PINNACLE data showed:

• 18% reduction in moderate/severe exacerbations versus glycopyrrolate alone (p=0.0168) 3
• 15% reduction versus formoterol alone (p=0.0628) 3
• Exacerbation benefits were most pronounced in patients with CAT ≥15 and documented exacerbation history 3

When to Consider Triple Therapy Instead

If your patient has moderate-to-very severe COPD with ≥2 exacerbations in the previous year despite dual bronchodilator therapy, consider escalating to triple therapy (budesonide/glycopyrrolate/formoterol 320/18/9.6 mcg or 160/18/9.6 mcg twice daily) 4. Triple therapy reduces exacerbations by 24-25% compared to dual bronchodilator therapy in this population 4.

• Triple therapy is particularly appropriate when blood eosinophil count ≥150 cells/mm³ 5
• The 160 mcg budesonide dose provides similar exacerbation reduction to 320 mcg with potentially lower ICS-related risks 4
• Be aware that pneumonia incidence increases from 2.3% with dual bronchodilators to 3.5-4.5% with ICS-containing regimens 4

Cardiovascular and Safety Monitoring

Use with extreme caution in patients with cardiovascular disease, as formoterol can cause clinically significant increases in pulse rate, blood pressure, and QTc prolongation 1:

• At therapeutic doses, expect mean pulse rate increases up to 26 bpm and QTc prolongation up to 25 msec (Bazett's correction) 1
• Monitor for paradoxical bronchospasm, which requires immediate discontinuation 1
• Watch for hypokalemia and hyperglycemia, though these are infrequent at recommended doses 1

Common Pitfalls to Avoid

• Never increase the daily dose beyond 18/9.6 mcg twice daily - if symptoms worsen or SABA use increases, re-evaluate the entire treatment regimen rather than increasing GFF MDI dose 1
• Do not use GFF MDI as monotherapy in patients with asthma, as long-acting beta-2 agonists increase asthma-related death risk when used without ICS 1
• Increasing SABA use signals disease deterioration requiring prompt medical attention, not simply more GFF MDI 1
• The terminal elimination half-life is 7 hours, so steady-state is achieved within 2-3 days of twice-daily dosing 1